Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-1230P is a processed pseudogene belonging to the U6 small nuclear RNA (snRNA) gene family. U6 snRNA is a highly conserved component of the spliceosome, essential for pre-mRNA splicing in eukaryotic cells[1][3]. The human genome contains many U6 snRNA pseudogenes, including RNU6-1230P, formed by retrotransposition events primarily mediated by LINE-1 (L1) elements[4]. These pseudogenes are non-functional: they are typically not transcribed into stable RNAs and do not participate in spliceosome assembly or catalysis. Instead, they serve as genomic markers of retrotransposition activity and the evolutionary history of snRNA genes[4][5]. There is no evidence that RNU6-1230P or other U6 pseudogenes are involved in disease processes or are actionable drug targets.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 1230, pseudogene (RNU6-1230P).